Previous 10 | Next 10 |
Vascular Biogenics Ltd. (VBLT) Q4 2018 Results Conference Call March 28, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Erez Feige - VP of Business Operations Conference Call Participants Swayampakula Ramakanth - H.C...
VBL Therapeutics (NASDAQ: VBLT ): FY GAAP EPS of -$0.62 beats by $0.07. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancer Signed strategic agreement for VB-201 for veterinary use; potential payments to VBL may exceed...
TEL AVIV, Israel, March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 201...
Altimmune (NASDAQ: ALT ) +44% on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...
VBL Therapeutics (NASDAQ: VBLT ) is up 11% premarket on modestly higher volume on the heels of new data on anti-cancer gene therapy ofranergene obadenovec (VB-111). The results were presented at the SGO Annual Meeting on Women's Cancer in Honolulu. More news on: Vascular Biog...
TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111 has potential to stimulate the immune system to induce a strong and durable respo...
TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audi...
TEL AVIV, Israel, March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase...
TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of var...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...